Effect of morphine on cell-mediated immune responses of human lymphocytes against allogeneic malignant cells

Journal of Experimental and Clinical Cancer Research

Volumn 24, Issue 2, 2005, Pages 255-263

  Fuggetta, Maria Pia ^a   Di Francesco, P ^b   Falchetti, R ^a   Cottarelli, A ^a   Rossi, L ^b   Tricarico, M ^a   Lanzilli, G ^a  

^a CNR   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cytotoxic T lymphocytes (CTL); HTLV 1; Interferon (IFN) gamma; Morphine (MOR); Natural killer cells (NK)

Indexed keywords

ALLOANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; MORPHINE; NARCOTIC ANALGESIC AGENT; OPIATE;

ARTICLE; CANCER CELL CULTURE; CANCER PAIN; CELL STRAIN K 562; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFECT; ERYTHROLEUKEMIA CELL; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; IMMUNE RESPONSE; IN VITRO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION;

ANALGESICS, OPIOID; CD8-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY, IMMUNOLOGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNE SYSTEM; IMMUNITY, CELLULAR; K562 CELLS; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE TRANSFUSION; LYMPHOCYTES; MORPHINE; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, HOMOLOGOUS;

EID: 22844436846     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Bercovitch M., Adunsky A.: Patterns of high-dose morphine use in a home-care hospice service. Should we be afraid of it? Cancer 101:1473-1477, 2004.
2. Pearl M.L., McCauley D.L., Thompson J., Mahler L., Valea F.A., Chalas E.: A randomized controlled trial of early oral analgesia in gynecologic oncology patients undergoing intra-abdominal surgery. Obstet. Gynecol. 99:704-708, 2002.
3. Barclay S., Todd C., Grande G., Lipscombe J.: Controlling cancer pain in primary care: the prescribing habits and knowledge base of general practitioners. J. Pain Symptom Manage 23:383-392, 2002.
4. Carpenter G.W., Carr D.J.: Pretreatment with beta-funaltrexamine blocks morphine-mediated suppression of CTL activity in alloimmunized mice. Immunopharmacology 29:129-140, 1995.
5. Carpenter G.W., Breeden L., Carr D.J.: Acute exposure to morphine suppresses cytotoxic T-lymphocyte activity. Int. J. Immunopharmacol. 17:1001-1006, 1995.
6. Scott M., Carr D.J.: Morphine suppresses the alloantigen-driven CTL response in a dose-dependent and naltrexone reversible manner. J. Pharmacol. Exp. Ther. 278:980-988, 1996.
7. Carrigan K.A., Saurer T.B., Ijames S.G., Lysle D.T.: Buprenorphine produces naltrexone reversible alterations of immune status. Int. Immunopharmacol. 4:419-428, 2004.
8. Carrigan K.A., Lysle D.T.: Morphine-6 beta-glucuronide induces potent immunomodulation. Int. Immunopharmacol. 1:821-831, 2001.
9. Peterson P.K., Molitor T.W., Chao C.C.: Mechanisms of morphine-induced immunomodulation. Biochem. Pharmacol. 46:343-348, 1993.
10. Nelson C.J., Dykstra L.A., Lysle D.T.: Comparison of the time course of morphine's analgesic and immunologic effects. Anesth. Analg. 85:620-626, 1997.
11. Lysle D.T., Coussons M.E., Watts V.J., Bennett E.H., Dykstra L.A.: Morphine-induced alterations of immune status: dose dependency, compartment specificity and antagonism by naltrexone. J. Pharmacol. Exp. Ther. 265:1071-1078, 1993.
12. Carr D.J., Serou M.: Exogenous and endogenous opioids as biological response modifiers. Immunopharmacology 31:59-71, 1995.
13. Fecho K., Maslonek K.A., Dykstra L.A., Lysle D.T.: Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats. J. Pharmacol. Exp. Ther. 277:633-645, 1996.
14. Nelson C., Schneider F., Lysle D.: Involvement of central mu- but not delta- or kappa- opioid receptors in immunomodulation. Brain Behav. Immun. 14:170-184, 2000.
15. Pruett S.B., Han Y., Munson A.E., Fuchs B.A.: Assessment of cholinergic influences on a primary humoral immune response. Immunology 77:428-435, 1992.
16. Alonzo N.C., Bayer B.M.: Opioids, immunology, and host defenses of intravenous drug abusers. Infect. Dis. Clin. North Am. 16:553-569, 2002.
17. Nath A., Hauser K.F., Wojna V., Booze R.M., Maragos W., Prendergast M., et al.: Molecular basis for interactions of HIV and drugs of abuse. J. Acquir. Immune Defic. Syndr. 31 Suppl. 2:S62-9, 2002.
18. Farrell H.E., Davis-Poynter N.J.: From sabotage to camouflage: viral evasion of cytotoxic T lymphocyte and natural killer cell-mediated immunity. Semin. Cell Dev. Biol. 9:369-378, 1998.
19. Miyoshi I., Kubonishi I., Yoshimoto S., Akagi T., Othsuki Y., Shiraishi Y., et al: Type C virus particles in a cord blood T-cell line derived by cocultivation of normal human lymphocytes and human leukemic T cells. Nature 296:770-771, 1981.
20. Macchi B., D'Onofrio C., Labianca R.A., Bonmassar E.: Mononuclear cells from peripheral blood of adult donors and from cord blood are equally protected by alpha- and beta-interferons against infection with HTLV-I. Pharmacol. Res. 22:503-514, 1990.
21. + T cells from influenza virus-immune mice. Immunology 95:346-351, 1998.
22. Sander B., Andersson J., Andersson U.: Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol. Rev. 119:65-93, 1991.
23. Saurer T.B., Carrigan K.A., Ijames S.G., Lysle D.T.: Morphine-induced alterations of immune status are blocked by the dopamine D2-like receptor agonist 7-OH-DPAT. J. Neuroimmunol. 148:54-62, 2004.
24. Roy S., Wang J., Gupta S., Charboneau R., Loh H.H., Barke R.A.: Chronic morphine treatment differentiates T helper cells to Th2 effector cells by modulating transcription factors GATA 3 and T-bet. J. Neuroimmunol. 147:78-81, 2004.
25. Friedman H., Eisenstein T.K.: Neurological basis of drug dependence and its effects on the immune system. J. Neuroimmunol. 147:106-108, 2004.
26. Nair M.P., Schwartz S.A., Polasani R., Hou J., Sweet A., Chadha K.C.: Immunoregulatory effects of morphine on human lymphocytes. Clin. Diagn. Lab. Immunol. 4:127-132, 1997.
27. Eisenstein T.K., Hilburger M.E.: Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J. Neuroimmunol. 83:36-44, 1998.
28. Palm S., Mignat C., Kuhn K., Umbreit H., Barth J., Stuber F., et al.: Phytohemagglutinin-dependent T-cell proliferation is not impaired by morphine. Methods Find Exp. Clin. Pharmacol. 18:159-165, 1996.
29. Bocchini G., Bonanno G., Canevari A.: Influence of morphine and naloxone on human peripheral blood T-lymphocytes. Drug Alcohol Depend. 11:233-237, 1983.
30. Sharp B.M.: Opioid receptor expression and intracellular signaling by cells involved in host defense and immunity. Adv. Exp. Med. Biol. 521:98-105, 2003.
31. Bayer B.M., Daussin S., Hernandez M., Irvin L.: Morphine inhibition of lymphocyte activity is mediated by an opioid dependent mechanism. Neuropharmacology 29:369-374, 1990.
32. Mellon R.D., Bayer B.M.: Role of central opioid receptor subtypes in morphine-induced alterations in peripheral lymphocyte activity. Brain Res. 789:56-67, 1998.
33. + T cells. Clin. Exp. Immunol. 118:428-434, 1999.
34. + T cells by antigen-specific stimulation. Cell. Immunol. 164:57-64, 1995.
35. Chao C.C., Hu S., Molitor T.W., Zhou Y., Murtaugh M.P., Tsang M., et al.: Morphine potentiates transforming growth factor-beta release from human peripheral blood mononuclear cell cultures. J. Pharmacol. Exp. Ther. 262:19-24, 1992.
36. Nyland S.B., Cao C., Bai Y., Loughran T.P., Ugen K.E.: Modulation of infection and type 1 cytokine expression parameters by morphine during in vitro coinfection with human T-cell leukemia virus type I and HIV-1. J. Acquir. Immune Defic. Syndr. 32:406-416, 2003.
37. Nyland S.B., Specter S., Im-Sin J., Ugen K.E.: Opiate effects on in vitro human retroviral infection. Adv. Exp. Med. Biol. 437:91-100, 1998.
38. Wang J., Barke R.A., Charboneau R., Loh H.H., Roy S.: Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J. Biol. Chem. 278:37622-37631, 2003.